Basic Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida, United States.
Mol Pharm. 2013 May 6;10(5):1557-65. doi: 10.1021/mp300352c. Epub 2013 Mar 5.
Amyloid-β (Aβ) deposition in the brain vasculature results in cerebral amyloid angiopathy (CAA), which occurs in about 80% of Alzheimer's disease (AD) patients. While Aβ42 predominates parenchymal amyloid plaques in AD brain, Aβ40 is prevalent in the cerebrovascular amyloid. Dutch mutation of Aβ40 (E22Q) promotes aggressive cerebrovascular accumulation and leads to severe CAA in the mutation carriers; knowledge of how DutchAβ40 drives this process more efficiently than Aβ40 could reveal various pathophysiological events that promote CAA. In this study we have demonstrated that DutchAβ40 shows preferential accumulation in the blood-brain-barrier (BBB) endothelial cells due to its inefficient blood-to-brain transcytosis. Consequently, DutchAβ40 establishes a permeation barrier in the BBB endothelium, prevents its own clearance from the brain, and promotes the formation of amyloid deposits in the cerebral microvessels. The BBB endothelial accumulation of native Aβ40 is not robust enough to exercise such a significant impact on its brain clearance. Hence, the cerebrovascular accumulation of Aβ40 is slow and may require other copathologies to precipitate into CAA. In conclusion, the magnitude of Aβ accumulation in the BBB endothelial cells is a critical factor that promotes CAA; hence, clearing vascular endothelium of Aβ proteins may halt or even reverse CAA.
脑血管中的淀粉样蛋白-β (Aβ) 沉积导致脑淀粉样血管病 (CAA),约 80%的阿尔茨海默病 (AD) 患者存在 CAA。虽然 Aβ42 在 AD 脑的实质淀粉样斑块中占优势,但 Aβ40 在脑血管淀粉样物中更为常见。Aβ40 的荷兰突变 (E22Q) 促进了脑血管的侵袭性积累,并导致突变携带者发生严重的 CAA;了解荷兰 Aβ40 如何比 Aβ40 更有效地驱动这一过程,可以揭示促进 CAA 的各种病理生理事件。在这项研究中,我们已经证明,由于其血液到大脑的转胞吞作用效率低下,荷兰 Aβ40 优先在血脑屏障 (BBB) 内皮细胞中积累。因此,荷兰 Aβ40 在 BBB 内皮细胞中建立了一个渗透屏障,阻止其自身从大脑中清除,并促进大脑微血管中淀粉样沉积物的形成。天然 Aβ40 在 BBB 内皮细胞中的积累不够强大,无法对其大脑清除产生如此显著的影响。因此,Aβ40 的脑血管积累速度较慢,可能需要其他共病来沉淀为 CAA。总之,Aβ 在 BBB 内皮细胞中的积累程度是促进 CAA 的一个关键因素;因此,清除血管内皮中的 Aβ 蛋白可能会阻止甚至逆转 CAA。